HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection.
Market Cap | 938.088 Million | Shares Outstanding | 20.079 Million | Avg 30-day Volume | 164.086 Thousand |
P/E Ratio | -25.5 | Dividend Yield | EPS | -1.83 | |
Price/Sales | 13.42 | Price cash flow ratio | 131.4 | Price free cash flow ratio | -150.5 |
Book Value | 22.69 | Price to Tangible Book | 2.06 | Alpha | 0.01 |
Short Interest Ratio | % Short Interest to Float | R-squared | 0.033921 | ||
BETA | 0.535289 | 52-week High/Low | 59.63 / 38.4 | Stddev | 0.12789 |
Q3 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 1 | 1 | 0.0% | 1 (0.07%) | 1 (0.06%) | 0.0% |
Funds Holding: | 166 | 179 | -7.26% | 50 (3.29%) | 54 (3.5%) | -7.41% |
13F shares: | 18.622 Million | 18.097 Million | 2.9% | 7.496 Million | 7.024 Million | 6.71% |
% Ownership | 92.7753 | 90.4649 | 2.55% | 37.3429 | 35.1132 | 6.35% |
New Positions: | 15 | 39 | -61.54% | 4 | 16 | -75.0% |
Increased Positions | 75 | 64 | 17.19% | 25 | 17 | 47.06% |
Closed Positions | 23 | 14 | 64.29% | 7 | 6 | 16.67% |
Reduced Positions | 54 | 52 | 3.85% | 19 | 16 | 18.75% |
Total Calls | 1 | 32.607 Thousand | -100.0% | 4.1 Thousand | ||
Total Puts | 53.284 Thousand | 59.601 Thousand | -10.6% | 34 Thousand | 26 Thousand | 30.77% |
PUT/CALL Ratio | 53,284.0 | 1.83 | 2911593.99% | 6.34 | 840341.64% | |
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
6 Thousand total shares from 1 transactions
27.5 Thousand total shares from 6 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
MELLETT PAUL J TREASURER AND CFO |
|
61,759 | 2021-01-08 | 6 |
OR YAT SUN SR. VP & CSO |
|
317,225 | 2020-12-15 | 3 |
LULY JAY R. PRESIDENT AND CEO |
|
681,488 | 2020-12-15 | 3 |
GARDINER NATHANIEL S. SR. VP & GENERAL COUNSEL |
|
58,893 | 2020-12-15 | 6 |
ADDA NATHALIE SR. VP & CHIEF MEDICAL OFFICER |
|
26,944 | 2020-12-15 | 3 |
KIEFFER TARA LYNN SR. VP, NEW PRODUCT DEV. |
|
0 | 2020-12-07 | 2 |
|
0 | 2020-06-29 | 2 | |
|
0 | 2020-02-26 | 1 | |
|
0 | 2020-02-26 | 1 | |
|
0 | 2020-02-26 | 1 | |
|
0 | 2020-02-26 | 1 | |
|
0 | 2020-02-26 | 1 | |
|
0 | 2019-02-28 | 0 | |
OCAIN TIM SENIOR VICE PRESIDENT |
|
17,547 | 2019-02-12 | 0 |
|
0 | 2016-02-11 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-01-08 20:57:13 -0500 | 2021-01-08 | S | 6,000 | $45.58 | d | 61,759 | direct | yes | 0.2677 | -1.215 | 0.2677 | 2 | -3.8921 | 3 | ||
2020-12-16 18:51:55 -0500 | 2020-12-15 | M | 5,250 | d | 0 | direct | ||||||||||
2020-12-16 18:43:32 -0500 | 2020-12-15 | M | 2,625 | d | 0 | direct | ||||||||||
2020-12-16 18:35:10 -0500 | 2020-12-15 | M | 5,250 | d | 0 | direct | ||||||||||
2020-12-16 18:27:09 -0500 | 2020-12-15 | M | 5,250 | d | 0 | direct | ||||||||||
2020-12-16 18:20:06 -0500 | 2020-12-15 | M | 7,500 | d | 0 | direct | ||||||||||
2020-12-16 18:51:55 -0500 | 2020-12-15 | F | 1,540 | $42.52 | d | 42,248 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | |||
2020-12-16 18:43:32 -0500 | 2020-12-15 | F | 770 | $42.52 | d | 55,759 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | |||
2020-12-16 18:35:10 -0500 | 2020-12-15 | F | 1,540 | $42.52 | d | 26,944 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | |||
2020-12-16 18:27:09 -0500 | 2020-12-15 | F | 1,540 | $42.52 | d | 317,225 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | |||
2020-12-16 18:20:06 -0500 | 2020-12-15 | F | 2,201 | $42.52 | d | 681,488 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | |||
2020-12-16 18:51:55 -0500 | 2020-12-15 | M | 5,250 | a | 43,788 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | ||||
2020-12-16 18:43:32 -0500 | 2020-12-15 | M | 2,625 | a | 56,529 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | ||||
2020-12-16 18:35:10 -0500 | 2020-12-15 | M | 5,250 | a | 28,484 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | ||||
2020-12-16 18:27:09 -0500 | 2020-12-15 | M | 5,250 | a | 318,765 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | ||||
2020-12-16 18:20:06 -0500 | 2020-12-15 | M | 7,500 | a | 683,689 | direct | 1.4036 | -1.2885 | 1.4036 | 2 | -2.6691 | 5 | ||||
2020-12-08 19:16:32 -0500 | 2020-12-07 | A | 65,000 | a | 65,000 | direct | ||||||||||
2020-12-07 17:38:43 -0500 | 2020-12-03 | M | 1,667 | $30.00 | a | 38,538 | direct | -0.3283 | 0.3986 | 11.7702 | 14.1618 | 24 | -2.837 | 4 | ||
2020-12-07 17:38:43 -0500 | 2020-12-03 | M | 1,667 | d | 13,667 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |